Close menu




July 3rd, 2025 | 07:05 CEST

Plug Power +71%! CAUTION with Evotec! Buy Walmart partner MiMedia shares?

  • Digitization
  • cloud
  • Software
  • Biotechnology
Photo credits: pixabay.com

A 71% share price increase in one month. Is this the resurrection of Plug Power shares? The performance is certainly impressive: operational news, insider buying, and a short squeeze are creating a dynamic mix. However, the fundamental problems remain. Those looking for an exciting stock for the second half of the year should take a closer look at MiMedia. The report on the first six months of this cloud hidden gem is expected to be positive and could drive the stock to a new high after its sideways movement. And what is Evotec doing? After last week's positive news, hopes for an upward trend were high. However, analysts are warning of a possible profit warning at the biotech company.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , MIMEDIA HOLDINGS INC | CA60250B1067 , PLUG POWER INC. DL-_01 | US72919P2020

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    MiMedia: Exciting stock for the second half of the year

    The chances are good that MiMedia's stock will break out of its sideways movement. When the Company reports on the first half of 2025, significant progress in market penetration should be evident. MiMedia is a provider of cloud-based storage solutions for personal media files, including photos, videos, music, documents, and text messages. Through apps and desktop clients, the platform offers a seamless cross-platform user experience with a focus on private and secure data backup.**

    MiMedia recently entered into a significant partnership with Chinese smartphone manufacturer Coolpad. The aim of this cooperation is to pre-install the MiMedia cloud platform on up to 5 million devices over a period of two years. The integration will take place both in new devices and via software updates for existing users. Coolpad, which has a particularly strong presence in emerging markets such as India, Southeast Asia, and Africa, will thus provide MiMedia with access to a large and growing user base. The partnership strengthens MiMedia's global reach and lays the foundation for recurring revenue through paid storage subscriptions and additional services within the app.

    Even more exciting was the news in March: MiMedia announced a high-profile partnership with Walmart Latin America. Under the agreement, the MiMedia app will be integrated into over 18 million smartphones in Mexico via Palmaris' mobile brand "Bait" – both on new devices and via an OTA update on existing Android phones. In addition, MiMedia will become part of Walmart's digital ecosystem, which includes the popular services 'Cashi' (digital wallet) and 'Salud' (health platform). This link offers potential access to a user base of over 46 million people. For MiMedia, this not only means market penetration, but also the opportunity to embed the use of its services in existing everyday applications – a significant competitive advantage in the cloud sector.

    With its partnerships with Coolpad and Walmart Latin America, MiMedia is establishing two clear strategic footholds in Asia and Latin America. Both collaborations aim to significantly scale the user base and position MiMedia as a potential global provider in the personal cloud services sector. This presents an exciting growth profile for investors: if MiMedia succeeds in activating and monetizing part of its target user base, the stock – which is also traded on the Stuttgart and Frankfurt stock exchanges (current price: EUR 0.33) – should still have significant upside potential.

    Plug Power: A breakthrough?

    Plug Power shares are looking back on a strong June - the shares of the struggling hydrogen pure play gained around 70%.

    The jump in the share price in recent days is due to a decision by the US government: The current tax package ("Big, Beautiful Bill") includes a two-year extension of the tax credit for clean hydrogen – from the original end date in 2026 to January 1, 2028. Plug Power, as a major US specialist in hydrogen systems and production, is likely to benefit from this. In the event of the subsidy being discontinued, there had already been speculation about the insolvency of the former hydrogen favorite. The short ratio is likely to have been correspondingly high, and this will probably have been a catalyst for the recent jump in the share price, as short sellers are likely to have covered their positions.

    At the beginning of the month, rumors about the possible extension of subsidies and purchases had already caused a stir. However, there were also operational reasons for the strong performance in June. Plug Power announced a billion-dollar deal with Allied Green Ammonia. According to the agreement, the existing partnership was expanded to include a 2 GW electrolyzer project in Uzbekistan. The project volume is USD 5.5 billion. Finally, CFO Paul Middleton contributed to the buying mood for Plug Power shares. He reported several insider purchases in June, sending a vote of confidence in the Company.

    The June rally is therefore based on a combination of operational news, insider purchases, and a short squeeze. However, investors should not ignore the fact that Plug Power remains in fundamental trouble. The US company is struggling with weak growth and high losses.

    Evotec: Profit warning?

    Has Evotec's momentum already faded? Last week, the German biotech company announced that it had joined the renowned British research network NURTuRE-AKI. The consortium is dedicated to researching acute kidney injury (AKI) and is coordinated by Kidney Research UK. As part of this partnership, Evotec will use its AI-powered platform "PanHunter" to analyze large amounts of clinical and molecular biological data. The aim is to identify new biomarkers and therapeutic approaches that could significantly improve the diagnosis and treatment of AKI.

    The move strengthens Evotec's position as a research-driven biotech company focused on complex disease states. Particularly in the field of kidney medicine, which has often been neglected in the past, this commitment represents a strategic expansion of the scientific network. The collaboration also underpins Evotec's business model of supporting biopharmaceutical partners in the development of personalized and data-driven drugs.

    Evotec's share price has gained over 10% since the beginning of last week and is trading above EUR 7 again. According to Warburg Research, there is still more to come. They see the fair value of the biotech stock at EUR 11.30. However, analysts expect a profit warning. Evotec is 1 of 16 companies on the "Warburg Guide to Warnings" list. Nevertheless, the stock is recommended as a "Buy".


    MiMedia's stock is ripe for a jump. With a positive report on the first six months, it should be able to break out of its sideways trend. Plug Power investors should not be too dazzled by the June rally. The Company continues to struggle with weak growth and high operating losses. If Warburg is right, a profit warning at Evotec would likely quickly wipe out the recent price gains.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by Fabian Lorenz on September 19th, 2025 | 07:10 CEST

    +19% in one day! SHORT SQUEEZE at D-Wave Quantum? What is going on with TeamViewer? STOCK MARKET NEWCOMER Finexity enters the billion-dollar market!

    • Tokenization
    • computing
    • Technology
    • Digitization

    D-Wave Quantum's stock exploded by 19% on Wednesday and held up well yesterday. Is this the start of a short squeeze? We had only just pointed out the high short ratio on Tuesday. Now, the Company has reached a new all-time high and has gained over 2,100% in just 12 months. Finexity shareholders would likely love to see a similar performance. But one step at a time. First, the newcomer has to establish itself on the stock market. Investors now have a chance to get in early on an exciting business model. Meanwhile, does TeamViewer offer a buying opportunity after its 30% drop? Technically, the stock is in bad shape, but operationally, the German technology company is performing better than the chart suggests.

    Read

    Commented by Fabian Lorenz on September 18th, 2025 | 07:25 CEST

    Adidas to take over Puma? Evotec with insider buying! 50% upside potential with AI stock NetraMark!

    • AI
    • Biotechnology
    • Technology
    • Sportswear
    • Investments

    Adidas and Puma caught in merger fever? A US investor brings the spectacular idea into play. Is it a means of exerting pressure on Puma's management or a real possibility? What do analysts say? Meanwhile, Evotec is sending a signal of confidence with fresh insider purchases. However, the stock is still digesting the recent revenue forecast downgrade. Could there be fresh momentum next week? In contrast, NetraMark shares offer a 50% return. For this to happen, however, the AI-driven drug development specialist must reach the analysts' price target. Operationally, there is much to be said for this, and in comparative tests, the Company has outperformed ChatGPT and DeepSeek.

    Read

    Commented by Armin Schulz on September 18th, 2025 | 07:15 CEST

    Novo Nordisk, PanGenomic Health and Pfizer - Who are the winners of the digital health revolution?

    • Healthcare
    • healthtech
    • Digitization
    • Technology
    • Biotechnology

    The disruptive force of the digital health revolution is fundamentally changing the healthcare industry. Artificial intelligence, data-driven therapies, and digital diagnostics are opening up billion-dollar markets and catapulting agile players to the forefront. These pioneers are setting new standards in patient-centered care and generating exponential growth in the process. This ecosystem opens up unique opportunities for strategic investors. Today, we take a look at Novo Nordisk's restructuring, PanGenomic Health's AI-driven innovations, and the political uncertainties at Pfizer.

    Read